Slide 1: Conference Call First-Quarter 2018 Results
Conference Call First-Quarter 2018 Results Joachim Kreuzburg, CEO Rainer Lehmann, CFO April 24, 2018
Slide 2: Disclaimer
Disclaimer This presentation contains statements concerning the future performance of the Sartorius Group and the Sartorius Stedim Biotech Group. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarante
Slide 3: Agenda
Agenda 01 Sartorius Group: Q1 2018 Results | FY 2018 Guidance 02 Sartorius Stedim Biotech Group: Q1 2018 Results | FY 2018 Guidance 03 Questions & Answers
Slide 4: Q1 2018 Highlights
Q1 2018 Highlights Dynamic start into 2018 in line with expectations Lab Products & Services division with double-digit growth rates Continued positive momentum in Bioprocess Solutions division Significant FX headwinds; especially from USD/EUR FY 2018 guidance confirmed 4
Slide 5: Dynamic start into the year but significant FX headwinds
Dynamic start into the year but significant FX headwinds Sartorius Group in millions of € unless otherwise specified Q1 2017 Q1 2018 in % in % cc 1 Sales revenue 343.1 364.9 +6.3 +11.4 Order intake 376.9 404.8 +7.4 +12.4 Underlying EBITDA2 84.6 88.6 +4.7 Underlying EBITDA2 margin in % 24.7 24.3 -0.4
Slide 6: Well balanced regional contributions to sales growth
Well balanced regional contributions to sales growth Americas EMEA Asia|Pacific Sales by Region € in millions € in millions € in millions in % 159.3 EMEA ~ 44% 151.2 111.9 116.6 89.0 Americas ~ 32% 80.0 ~ €365m Asia|Pacific ~ 24% Q1 17 Q1 18 Q1 17 Q1 18 Q1 17 Q1 18 +13.8 % +6.3 % +18.2 % Acc. to cus
Slide 7: BPS: Robust growth but FX headwinds
BPS: Robust growth but FX headwinds Order Intake Sales Revenue Underlying EBITDA & Margin € in millions € in millions € in millions +9.1% cc +10.0% cc +2.9% +4.1% +4.9% 283.5 295.1 251.1 263.4 68.4 70.3 27.2% 26.7% Q1 17 Q1 18 Q1 17 Q1 18 Q1 17 Q1 18 Solid development in both sales revenue and ord
Slide 8: LPS: Double-digit growth in sales revenue and profit
LPS: Double-digit growth in sales revenue and profit Order Intake Sales Revenue Underlying EBITDA & Margin € in millions € in millions € in millions +22.7% cc +15.3% cc +12.6% +17.3% +10.3% 109.6 101.4 18.3 93.4 92.0 16.3 18.0% 17.7% Q1 17 Q1 18 Q1 17 Q1 18 Q1 17 Q1 18 Overproportionate increase i
Slide 9: Cash flow influenced by higher earnings and lower taxes
Cash flow influenced by higher earnings and lower taxes Sartorius Group € in millions Q1 2017 Q1 2018 in % Increase in extraordinary items in line with expectations; Underlying EBITDA 84.6 88.6 +4.7 mainly reflects integration costs Extraordinary items -6.1 -7.2 -17.4 of Essen BioScience Financial
Slide 10: Key financial indicators remain at robust levels
Key financial indicators remain at robust levels Key Financial Indicators Net Debt and Net Debt to Underlying EBITDA Sartorius Group Dec. 31, 2017 Mar. 31, 2018 1000 3.0 3 800 2.4 2.4 Equity ratio in % 35.1 35.4 600 1.8 1.8 Net debt in millions of € 895.5 900.4 400 1.2 1.2 200 0.6 0.6 Net debt | und
Slide 11: Outlook for 2018 confirmed
Outlook for 2018 confirmed FY 2017 FY 2018 Guidance1 Sales revenue Underlying Sales revenue Underlying growth1 EBITDA margin growth EBITDA margin Sartorius Group 9.3% 25.1% ~ 9% - 12% ~ +0.5pp Bioprocess Solutions 4.9% 28.0% ~ 8% - 11% ~ +0.5pp Lab Products & Services 22.0% 18.0% ~ 12% - 15% ~ +1.0p
Slide 12: Agenda
Agenda 01 Sartorius Group: Q1 2018 Results | Q1 2018 Guidance 02 Sartorius Stedim Biotech Group: Q1 2018 Results | Q1 2018 Guidance 03 Questions & Answers
Slide 13: Good start into the year with continued positive momentum
Good start into the year with continued positive momentum Sartorius Stedim Biotech Group in millions of € unless otherwise specified Q1 2017 Q1 2018 in % in % cc 1 Sales revenue 268.8 281.1 +4.6 +9.8 Order intake 302.1 313.8 +3.9 +9.0 Underlying EBITDA2 71.9 74.0 +3.0 Underlying EBITDA2 margin in %
Slide 14: Growth strong in Asia|Pacific and solid in EMEA and the Americas
Growth strong in Asia|Pacific and solid in EMEA and the Americas Americas EMEA Asia|Pacific Sales by Regions in € millions in € millions in € millions in % 117.4 122.5 94.1 93.8 EMEA ~ 44% 64.8 57.3 Americas ~ 33% ~ €281m Q1 17 Q1 18 Q1 17 Q1 18 Q1 17 Q1 18 +10.2% +5.0% +19.5% Asia|Pacific ~ 23% Acc
Slide 15: Significant increase in operating cash flow
Significant increase in operating cash flow Sartorius Stedim Biotech Group € in millions Q1 2017 Q1 2018 in % Increase in extraordinary items in line with expectations Underlying EBITDA 71.9 74.0 +3.0 Net operating cash flow Extraordinary items -2.0 -3.6 -82.2 influenced by lower tax Financial r
Slide 16: Financial position remains strong
Financial position remains strong Key Financial Indicators Net Debt and Net Debt to Underlying EBITDA Sartorius Stedim Biotech Dec. 31, 2017 Mar. 31, 2018 180 1.5 1.5 1.5 150 1.2 1.2 1.2 Equity ratio in % 62.6 62.8 120 0.9 0.9 0.9 90 0.6 0.6 0.6 Net debt in millions of € 127.1 118.4 60 30 0.3 0.3 0.
Slide 17: Outlook for 2018 confirmed
Outlook for 2018 confirmed FY 2017 FY 2018 Guidance Sales revenue growth1 4.1% ~ 7% - 10% Underlying EBITDA margin 27.3% ~ +0.5pp1 Capex ratio 12.6% ~ 15% 1 In constant currencies Growth guidance includes non-organic contribution by recent acquisition: ~ 0.5pp As a result from the US tax reform,
Slide 18: Agenda
Agenda 01 Sartorius Group: Q1 2018 Results | FY 2018 Guidance 02 Sartorius Stedim Biotech Group: Q1 2018 Results | FY 2018 Guidance 03 Questions & Answers
Slide 19: Thank you very much for your attention
Thank you very much for your attention